Orthofix International Announces Third Quarter Results And Additional Debt Payment Ahead of Scheduled Maturity

• Q309 sales totaled $135.1 million, up 4% from Q308; up 7% on a constant currency basis
• Sales of spinal implants & biologics were up 10%, to $28.5 million, vs. prior year; sales of spine stimulation products grew 12%, to $39.6 million
• Sales in the orthopedic business decreased 2%, but increased 6% on a constant currency basis
• Sales in the sports medicine business grew 4% in total, to a record $24.7 million; U.S. sales increased 6%
• Consolidated gross margin improved to 76.3%; operating margin increased to 13.1%
• Q309 reported net income was $0.36 per diluted share; excluding certain items, adjusted net income was $0.44 per diluted share
• The Company made an additional $5 million debt payment ahead of schedule maturity in October